# NURIX THERAPEUTICS, INC. (NRIX) FY2026 Q3 Balance Sheet

- Company: NURIX THERAPEUTICS, INC. (NRIX)
- Period: As of 2026-08-31
- Filing: Q3 FY2026 10-Q, filed 2026-10-13, accession number 0001549595-26-000049
- Page: https://plicit.ai/financials/nrix/fy2026-q3-balance-sheet
- Chart image: https://plicit.ai/charts/nrix-fy2026-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-08-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,195,298,000 US dollars
- **Current assets**: 1,103,692,000 US dollars
- **Non-current assets**: 91,606,000 US dollars
- **Liabilities**: 226,987,000 US dollars
- **Current liabilities**: 130,742,000 US dollars
- **Non-current liabilities**: 96,245,000 US dollars
- **Equity**: 968,311,000 US dollars
- **Cash and cash equivalents**: 720,242,000 US dollars
- **Marketable securities, current**: 328,013,000 US dollars
- **Prepaid expenses and other current assets**: 35,437,000 US dollars
- **Accounts receivable**: 20,000,000 US dollars
- **Operating lease right-of-use assets**: 48,631,000 US dollars
- **Property and equipment, net**: 19,407,000 US dollars
- **Marketable securities, non‑current**: 14,832,000 US dollars
- **Other assets**: 7,954,000 US dollars
- **Restricted cash**: 782,000 US dollars
- **Accrued expenses and other current liabilities**: 63,674,000 US dollars
- **Accounts payable**: 32,984,000 US dollars
- **Deferred collaboration funding, current**: 22,233,000 US dollars
- **Deferred revenue, current**: 8,610,000 US dollars
- **Operating lease liabilities, current**: 3,241,000 US dollars
- **Operating lease liabilities, net of current portion**: 62,091,000 US dollars
- **Deferred collaboration funding, net of current portion**: 23,376,000 US dollars
- **Deferred revenue, net of current portion**: 10,778,000 US dollars
- **Additional paid-in capital**: 1,598,540,000 US dollars
- **Common stock, $0.001 par value— 500,000,000 shares authorized as of August 31, 2026 and November 30, 2025; 109,200,394 and 101,807,484 shares issued and outstanding as of August 31, 2026 and November 30, 2025, respectively**: 109,000 US dollars
- **Preferred stock, $0.001 par value— 10,000,000 shares authorized as of August 31, 2026 and November 30, 2025; no shares issued and outstanding as of August 31, 2026 and November 30, 2025**: 0 US dollars
- **Accumulated deficit**: negative 630,128,000 US dollars
- **Accumulated other comprehensive income (loss)**: negative 210,000 US dollars
- **Gross equity (calculated)**: 1,598,649,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.